KYAN Technologies’ platform used to find drug combination and potential biomarker in radioresistant cancer study
In this study, KYAN’s Optim.AI™ platform (also known as “QPOP”), was applied to identify an epigenetic based therapeutic strategy in radioresistant head and neck cancer (RR-HNC). The study identified a critical role of HDAC6 in RR-HNC. Furthermore, a four‑gene biomarker signature that may predict HDAC6-related radioresistance was identified from two independent patient cohorts through multi-omic analysis that pairs functionomics with transcriptomics.
“We are extremely excited by the results of this study as it exhibits the value that we can add to drug development with combinatorial biomarker discovery,” said Hugo Saavedra, Chief Executive Officer of KYAN.
KYAN’s Chief Scientific Officer, Dr. Edward Chow, added, “We are very proud of the work done by our collaborators at National University of Singapore and National Cancer Centre Singapore to demonstrate the use of Optim.AI™ towards novel target identification in a difficult to treat cancer.”
About KYAN
KYAN is a biotech company committed to bridging the cancer care gap by advancing revolutionary technologies. The company’s flagship platform, Optim.AI™, combines small data AI-driven analytics with innovative biological experimentation to provide clinicians with personalized cancer treatment insights. Optim.AI™ is clinically validated and currently available as a laboratory developed test (LDT) to clinicians and patients in Singapore, Indonesia, Malaysia and Thailand. Multiple studies have demonstrated our platform’s accuracy and effectiveness across a variety of cancers. Visit our website www.kyantechnologies.com to explore our publications, presentations, and to learn more about Optim.AI™.
For media inquiries contact:
Sudha Sruthi, Corporate Development
+65 6974 0426
admin@kyantechnologies.com
Distribution channels: Healthcare & Pharmaceuticals Industry, Science, Technology
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release